Angioline

AngioLine will launch a new production facility for cardiovascular medical devices in the Biotechnopark in Koltsovo, Novosibirsk, in mid-September 2019. Investment is about 500 million rubles.

Novosibirsk-based company Angioline has invested 500 million rubles to launch production of three new medical devices for cardiovascular diseases: an aortic valve, a stent retriever, and an aortic stent graft. The production will be located at the Koltsovo biotechnopark, with launch expected by August 2019.

AO Angioline will invest over 500 million rubles (approx. $7.8 million) to build a plant in Novosibirsk, Russia, producing aortic valves, venous cava filters, occluders and vascular implants. The project is in partnership with the Meshalkin Research Center and is expected to launch in 2020.

Angioline will build a new 8,500 sq m facility in Koltsovo Biotechnopark for coronary stents and catheters, with investment of 500 million RUB and 250 new jobs. Construction runs 2017-2019, commissioning in 2020.